Drug Profile
Anti CD123 chimeric antigen receptor T-cell therapy - Nanjing Legend Biotech
Latest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator Nanjing Legend Biotech
- Developer Nanjing Legend Biotech; Second Affiliated Hospital of Xi'an Jiaotong University
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Leukaemia
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for phase-I development in Leukaemia(In children, In the elderly, Second-line therapy or greater, In adults) in China (IV)
- 03 Sep 2019 Nanjing Legend Biotech terminates a phase I trial in Leukaemia (Second-line therapy or greater, In children, In adults, In the elderly) in China due to adverse effect (IV) (NCT03672851)
- 17 Sep 2018 Phase-I clinical trials in Leukaemia (Second-line therapy or greater, In children, In adults, In the elderly) in China (IV) (NCT03672851)